OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Infectious Diseases is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Introducing the New Journal of Infectious Diseases Editorial Board, Part I	176
Introducing the New Journal of Infectious Diseases Editorial Board, Part II	135
CCL19 (rs3136658) and CCL21 (rs2812377) Variants Are Associated With Susceptibility and Related Mortality of SARS-CoV-2 Infection	128
Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019	109
Reviewers Vol 1 2023	107
CCL17 Influences Borrelia burgdorferi Infection in the Heart	90
sTREM-1 to Risk-Stratify Patients With Malaria: A Functional Crystal Ball to Improve Outcomes and Save Lives	86
Antiretroviral Therapy Ameliorates Simian Immunodeficiency Virus–Associated Myocardial Inflammation by Dampening Interferon Signaling and Pathogen Response in the Heart	82
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants	82
Neutrophil-Associated Proteins as Novel Biomarkers Elevated in the Cerebrospinal Fluid of Patients With Neurosyphilis	80
Integrating Ethics in Public Health Guideline Development: Case Study of Guidelines on Respiratory Isolation for Persons With Tuberculosis in Community Settings	74
The Sympathetic Nervous System Is Necessary for Development of CD4+ T-Cell Memory Following Staphylococcus aureus Infection	72
Serum Gasdermin D for Early Diagnosis of Bloodstream Infection and Differentiating Bacterial From Fungal Infections	69
Differences in Neutrophil Counts Between African and Non-African Countries in 2 International Clinical Trials	68
Unpredicted Protective Function of Fc-Mediated Inhibitory Antibodies for HIV and SARS-CoV-2 Vaccines	64
Revaccination for Hepatitis B in Previous Nonresponders Following Hepatitis C Eradication	60
Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates	56
A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants	56
Estimating the Potential Public Health Value of BCG Revaccination	55
Analysis of the Infectious Diseases Fellowship Program Directors Postmatch 2023 Survey	53
Emergency Myelopoiesis Distinguishes Multisystem Inflammatory Syndrome in Children From Pediatric Severe Coronavirus Disease 2019	53
EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus	53
High Mortality Rates Among Individuals Misdiagnosed With Tuberculosis: A Matched Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil	53
An Expression Quantitative Trait Locus of Fc Gamma Receptor Genes Is Associated With Antimalarial IgG Responses and Infection Levels in Burkinabe Families	52
Influenza Vaccine-Averted Illness in Chile, Guyana, and Paraguay During 2013–2018: A Standardized Approach to Assess the Value of Vaccination	49

A Call to Action: Current Challenges and Considerations for COVID-19 Vaccination in Immunocompromised Populations	49
Pneumococcal Carriage and Seroepidemiology Studies to Measure Current and Future Pneumococcal Conjugate Vaccine Effectiveness	48
Correction to: Rickettsia rickettsii subsp californica subsp nov, the Etiologic Agent of Pacific Coast Tic	47
T-Cell Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Measured by an Interferon-γ Release Assay Is Strongly Associated With Patient Outcomes in Vaccinated Persons Hospitalized With D	47
Comparison of Daily Versus Admission and Discharge Surveillance Cultures for Multidrug-Resistant Organism Detection in an Intensive Care Unit	47
Characterizing the Etiology of Recurrent Tuberculosis Using Whole Genome Sequencing: Alaska, 2008–2020	47
Assessment of Humoral Immune Responses to Repeated Influenza Vaccination in a Multiyear Cohort: A 5-Year Follow-up	47
Oral Microbiome Diversity Matters on Nucleos(t)ide Analogue Cessation in Chronic Hepatitis B	46
Bacterial Meningitis Epidemiology in Burkina Faso and Niger—High-Risk Countries in the Meningitis Belt of Sub-Saharan Africa, 2015–2023	46
Genomic Diversity and Antimicrobial Susceptibility of Invasive Neisseria meningitidis in South Africa, 2016–2021	45
Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal	45
The Vaginal Microbiota of Adult Malagasy Women of Reproductive Age in the Marovoay District: First Characterization and Exploration of Associations With Human Papillomavirus and	43
Harnessing Endogenous Peptide Compounds as Potential Therapeutics for Severe Influenza	43
Neither the African-Centric S47 Nor P72 Variant of TP53 Is Associated With Reduced Risk of Febrile Malaria in a Malian Cohort Study	41
Barriers and Strategies for Hepatitis B and C Elimination in Pakistan	41
Hepatitis B Surface Antigen Loss: What Does Integration Have to Do With a Functional Hepatitis B Virus Cure?	40